PATENT CLAIM ANALYSIS

Application Number: 15766612
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "264110"]

Abstract:
This invention is in the area of improved therapeutic combinations for and methods of treating selected cancers using specific Mer tyrosine kinase (MerTK) inhibitors in combination with immune checkpoint inhibitors. In one aspect, an improved treatment for select cancers is disclosed using specific Mer tyrosine kinase (MerTK) inhibitors, for example UNC2371, in combination with an immune checkpoint inhibitor, for example, a cytotoxic T-lymphocyte-associated protein 4 (CTLA4) inhibitor, a programmed cell death protein 1 (PD1) inhibitor, or a programmed death-ligand 1 (PDL-1) inhibitor.

Claim (Index 103):
The method of  claim 102 , wherein the antibody is nivolumab or pembrolizumab.

Metadata:
- Claim Count in Document: 67.0
- Percentile: 91.0
- Lexical Diversity: 1.83636
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15765168', '15303985', '14310848', '15419642', '15195723']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6511070561300232
- 35 USC 102 Novelty (BERT): 0.5516962059580965
- Combined Prediction Score: 0.6411659711128306
- Mean Citation Score: 362.903398
- Max Citation Score: 425.19928
- Similarity Product: 282.23724638519286

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test